FDA issues not approvable letter for Schering-Plough’s Sugammadex
Schering-Plough has acquired sugammadex in November 2007 through its acquisition of Organon BioSciences, which developed the product. Thomas Koestler, executive vice president and president of Schering-Plough Research Institute,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.